- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 04.06. | HCW Biologics Sinks on Alliance with WY Biotech | - | Baystreet.ca | ||
| 04.06. | HCW Biologics geht Partnerschaft mit WY Biotech für Immuntherapie ein | 1 | Investing.com Deutsch | ||
| 04.06. | HCW Biologics Inc.: HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech | 3 | GlobeNewswire (USA) | ||
| 30.05. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05. | HCW Biologics GAAP EPS of -$0.05, revenue of $5.1K | 1 | Seeking Alpha | ||
| 16.05. | HCW Biologics GAAP EPS of -$0.20, revenue of $1.1M | 3 | Seeking Alpha | ||
| 16.05. | HCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trial | 1 | FierceBiotech | ||
| 16.05. | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results | 109 | GlobeNewswire (Europe) | MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 15.05. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | HCW Biologics jumps 16% on pricing $5M follow on offering | 1 | Seeking Alpha | ||
| 14.05. | HCW Biologics Inc.: HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules | 1 | GlobeNewswire (USA) | ||
| 13.05. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.05. | HCW Biologics präsentiert neuartigen CAR-T-Zell-Verstärker | 5 | Investing.com Deutsch | ||
| 13.05. | HCW Biologics presents novel CAR-T cell enhancer | 2 | Investing.com | ||
| 13.05. | HCW Biologics Inc.: HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization | 134 | GlobeNewswire (Europe) | Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association... ► Artikel lesen | |
| 09.05. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,143 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,420 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,911 | +2,57 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,970 | -2,51 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,500 | +6,16 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,475 | +3,53 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 2,340 | 0,00 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | - | - | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1US15117F8077 Cellectar... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 8,000 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements | NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA... ► Artikel lesen | |
| IMMUNIC | 0,615 | +1,82 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,094 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 2,365 | 0,00 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,37 % bei einem Aktienkurs von 4,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.